<DOC>
	<DOCNO>NCT00458159</DOCNO>
	<brief_summary>A Phase I , Open-Label , Dose-Escalation Study CC-11006 In Subjects With Low- Intermediate-1 Risk Myelodysplastic Syndromes .</brief_summary>
	<brief_title>A Phase I , Open-Label , Dose-Escalation Study CC-11006 In Subjects With Low- Intermediate-1 Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Study Population Key Inclusion Criteria Age great 18 year . Able understand voluntarily sign informed consent form . A diagnosis de novo myelodysplastic syndrome ( MDS ) least 12 week duration , one follow subtypes ( See WHO Classification Criteria Myelodysplastic Syndromes ) . 1 . Refractory anemia ( RA ) 2 . Refractory cytopenia multilineage dysplasia ( RCMD ) 3 . Refractory anemia ring sideroblast ( RARS ) 4 . Refractory cytopenia multilineage dysplasia ring sideroblast ( RCMDRS ) 5 . Refractory anemia excess blast ( RAEB1 [ 59 % blast ] ) 6 . RAEB2 ( 10 % 19 % blast ) 7 . MDSUnclassified ( MDSU ) 8 . MDS chromosome 5q deletion ( MDS 5q ) At least two hemoglobin &lt; 9 g/dL ( untransfused ) transfusiondependence define require least 4 unit RBCs 56 day prior Study Day 1 ( start CC11006 treatment ) . Tried fail one conventional firstline treatment MDS anemia include Revlimid® , recombinant erythropoietin , 5azacitidine , decitibine associate therapy . More 28 day ( Study Day 1 ) must elapse since previous treatment ( include Revlimid® ) MDS anemia , transfusion ( ) . An ECOG Performance status 0 , 1 2 • Able adhere study visit schedule protocol requirement . Females childbearing potential ( FCBP ) † must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse least 28 day start study drug , study drug , dose interruption , 28 day last dose study drug . The two method reliable contraception must include one highly effective method ( i.e . intrauterine device , hormonal [ birth control pill , injection , implant ] , tubal ligation , partner 's vasectomy ) one additional effective ( barrier ) method ( i.e . latex condom , diaphragm , cervical cap ) . FCBP must refer qualified provider contraceptive method , need . Before start study drug : FCBP must two negative pregnancy test ( sensitivity least 50 mIU/mL ) prior start study drug . The first test must perform within 10 14 day second negative pregnancy test within 24 hour prior start study drug . The subject may receive study drug Investigator verify negative pregnancy test . Will counsel pregnancy precaution , potential risk fetal exposure . Male Subjects : Must agree use latex condom sexual contact female childbearing potential study drug treatment , dose interruption , least 28 day follow discontinuation study drug even undergone successful vasectomy . Agree abstain donate semen sperm take study drug 28 day stop study drug . While study dose interruption : FCBP regular cycle must agree pregnancy test weekly first 28 day every 28 day study drug , dose interruption day 28 day follow discontinuation study drug . If menstrual cycle irregular , pregnancy test must occur every 14 day . The subject may receive study drug Investigator verify negative pregnancy test . No 28day supply study drug dispense time . In addition require pregnancy test , Investigator must confirm FCBP continue use two reliable method birth control visit . Counseling pregnancy precaution must do minimum every 28 day . Subjects must remind potential risk fetal exposure visit share drug . Pregnancy test counsel must perform subject missed period abnormality pregnancy test menstrual bleeding . Study drug treatment must bediscontinued evaluation . Females must agree abstain breastfeeding study , dose interruption 28 day last dose study drug . Male Subjects : Counseling share drug , donate blood , sperm semen , contraceptive use , include counsel emergency contraception must do minimum every 28 day . Upon discontinuation study drug : Pregnancy test perform FCBP study termination day 28 last dose study drug . Females must agree abstain breastfeed 28 day last dose study drug . Male FCBP subject must follow birth control requirement require study drug 28 day last dose study drug . Both male female must agree abstain donate blood ovum ( female ) take study drug 28 day stop study drug . Males must donate sperm semen 28 day last dose study drug . If pregnancy occur treatment , study drug must immediately discontinue . Key Exclusion Criteria Myelosclerosis ( myelofibrosis ) occupy 30 % marrow space . Bone marrow blast ≥ 20 % . The following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 500 cells/L ( 0.5 x 109/L ) 2 . Platelet count &lt; 50,000/L ( 50 x 109/L ) 3 . Serum creatinine &gt; 2.0 mg/dL ( 177 mol/L ) 4 . Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) 5 . Serum total bilirubin &gt; 2 x ULN secondary hemolysis absence know intrinsic liver disease A history active tuberculosis require treatment within previous 3 year ( Study Day 1 ) opportunistic infection , include limited evidence active cytomegalovirus , active Pneumocystis carinii , atypical mycobacterium infection , etc. , document HIV infection , within previous 6 month ( Study Day 1 ) . Subjects evidence old tuberculosis infection without documented adequate therapy also exclude . A history active nonhematopoietic malignancy , similar diagnosis within 3 year Study Day 1 ( except basal cell squamous cell carcinoma skin cervical carcinoma situ ) . A history venous thromboembolism . Clinically significant anemia due factor iron , B12 folate deficiency , autoimmune hereditary hemolysis gastrointestinal bleeding ( marrow aspirate evaluable storage iron , transferrin saturation must &gt; 20 % serum ferritin le 50 ng/mL ) . Any clinically significant pulmonary , cardiac , vascular , endocrine , hepatic , neurological , gastrointestinal genitourinary disease unrelated underlying hematological disorder . Any lifethreatening active infection require parenteral antibiotic therapy . Chromosome abnormality common de novo acute myelogenous leukemia ( AML ) , i.e. , ( 8:21 ) , ( 15 ; 17 ) , inv ( 16 ) . Known hepatitisB surface antigenemia positive hepatitisC antibody . Known HIV1 positivity . Greater Grade 2 neuropathy . Any medical condition , include presence laboratory abnormality , would place subject unacceptable risk he/she participate study confounds ability interpret data study . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant lactating female . Subjects require ongoing treatment corticosteroid . Use cytotoxic chemotherapeutic agent experimental agent ( agent commercially available ) treatment MDS within 28 day first day study drug treatment . Recombinant human erythropoietin ( rHuEPO ) therapy within 28 day first day study drug treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>CC-11006</keyword>
	<keyword>RA</keyword>
	<keyword>MDS</keyword>
	<keyword>Celgene</keyword>
	<keyword>RCMD-RS</keyword>
	<keyword>RARS</keyword>
	<keyword>RAEB-1</keyword>
	<keyword>Low-or Intermediate-1-Risk Myelodysplastic Syndrome ( MDS )</keyword>
</DOC>